MedTrace Logo

Efficacy of Topical Pimecrolimus in the Treatment of Pityriasis Alba

NCT03834935 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2019-02-11

No results posted yet for this study

Summary

Pityriasis alba (PA) is a common benign skin disorder, that usually affects children and adolescents of darker phototypes. A history of atopic dermatitis is a well-known risk factor, and PA may be a minor manifestation of atopic dermatitis, although it can occur in nonatopic individuals as well. The objective is to evaluate the effect of topical pimecrolimus in the treatment of treatment of PA

Conditions

  • Pityriasis Alba

Interventions

DRUG

Elidel (pimecrolimus 1%)

topical application of product on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed

DRUG

Cold Cream

Topical application on all lesions, twice daily. Sunscreen will not be indicated, and hygienic habits will not be changed

Sponsors & Collaborators

  • St Joseph University, Beirut, Lebanon

    lead OTHER

Principal Investigators

  • Josiane Helou, MD · Saint-Joseph University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2021-02-01
Completion
2021-04-01

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03834935 on ClinicalTrials.gov